Q and A from the EMA on Biosimilars

See this post from the EMA:
Just published: Q&A on the interoperability of biosimilar medicines in the European Union.

This Q&A responds to questions raised by the publication of a statement on biosimilar interchangeability by EMA and the Heads of Medicines Agency last September.

Read the Q&A and find out more about biosimilar medicines:

Let us tell you more

We will email you to start the conversation